NCT05718622 Evaluation and Prediction of the Effect of EECP on HR-NICE Patients

Eligibility & Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 100 participants in total. It began in 2022-11-10 with a primary completion date of 2026-11-30.

Brief Summary

Stroke is one of the most threatening causes of mortality and disability worldwide. High risk non-disabling ischemic cerebrovascular events (HR-NICE), defined by mild stroke complicating with greater than 50% atherosclerotic stenosis in intracranial or extracranial arteries, is more likely to develop severe stroke in future. Currently, the clinical treatment for HR-NICE patients is limited to dual antiplatelet therapy or endovascular treatment, both of which are taken controversially due to the side effect or high risk. Enhanced external counterpulsation (EECP) is an established non-invasive treatment for circulatory support. By inflating repeatedly and sequentially from calves to hips in the early diastolic phase of every cardiac cycle, EECP has been demonstrated to increase the shear stress of blood vessels, enhance the collateral circulation and improve brain perfusion in patients with stroke. However, few studies have devoted exclusively to patients with HR-NICE. It is not clear whether EECP can improve the clinical performance or reduce the rate of recurrent stroke in 90 days. In this trial, HR-NICE patients will be divided into two groups according to true or sham EECP treatment. Based on multi-model magnetic resonance imaging, the investigators explore the central neural characteristic before and after EECP treatment.

Eligibility Criteria

Inclusion Criteria: * In accordance with the diagnostic criteria of Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018 * Patients who have had a clinically significant ischemic stroke for the first time and are currently stable * Unilateral internal carotid artery or middle cerebral artery was confirmed for the first time as moderate to severe stenosis (≥50%) or occlusion on digital subtraction angiography examination （DSA）. * Did not receive surgical treatment such as balloon dilation * National Institute of Health stroke scale (NIHSS) score ≤3 * The clinical data is completed and be able to consistently complete the study * Age 18-80, education level≥ 6 years and agree to sign informed consent Exclusion Criteria: * Progressive stroke * Diseases with severe damage to other organs * Moderate to severe aortic insufficiency * Dissection aneurysm, aortic aneurysm, cerebral aneurysm * Significant pulmonary hypertension * Various bleeding disorders, bleeding tendencies, or use of anticoagulants, Prothrombin international normalized ratio （INR） \>2.0 * Active phlebitis, venous embolism, venous thrombosis of lower extremity * The presence of infection in the body * Valvular disease, congenital heart disease, cardiomyopathy * Uncontrolled hypertension (\>170/110mmHg) * Uncontrolled arrhythmia * Left heart failure * Pregnancy * Patients with cardiac pacemakers * Patients with arterial clamp after craniocerebral operation * Patients with metal implants, such as metal joints, shrapnel and orbital foreign bodies * History of moderate to severe cognitive impairment or psychiatric disorders * History of malignancy * moyamoya patients * Lower extremity arterial thrombosis

Contact & Investigator

Frequently Asked Questions

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.